NGF and osteonecrosis: On December 23, 2010, the United States Food and Drug Administration (FDA) placed ongoing fulranumab studies on clinical hold because of a concern that the entire class of anti-NGF antibodies may be associated with a condition representing either rapidly progressing osteoarthritis or osteonecrosis [19].